Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Amphastar Pharmaceuticals, Inc

AMPH ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: HOLD

Last Close

$20.91

▲ +3.62%

Market Cap $889.47M · Vol 111.47K

Key Metrics

P/E Ratio

12.23

FWD: 7.03

Market Cap

$889.47M

Small Cap

Div Yield

N/A

EPS Growth

-8.88%

YoY

RSI (14)

63.67

Momentum

Beta

0.90

vs Market

52W High

$31.21

33.00% below

52W Low

$16.66

25.51% above

Volume

111.47K

Avg 168.21K

P/B

1.55

Price-to-book

ROE

20.59%

Return on equity

Free Float

69.18%

Public shares

Shariah Compliance8 STANDARDS

✗ Amphastar Pharmaceuticals, Inc (AMPH) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AMPH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.63%

+11.19%

+20.87%

-26.63%

YTD

-21.92%

-30.78%

-63.48%

+6.68%

Financials & Valuation

TTM · Annual

Total Revenue	$719.89M
Net Income	$98.09M
Revenue Growth (YoY)	+5.44%
Gross Margin	49.46%
Operating Margin	19.50%
Net Profit Margin	13.63%
ROE	20.59%
ROA · ROIC	7.71% · 8.66%

P/E Ratio	12.23
Forward P/E (FY1)	7.03
PEG Ratio	-0.39
P/S	1.79
P/B	1.55
P/FCF	10.85
EPS Growth	-8.88%
Outstanding Shares	42.54M

Technical Indicators

50-Day SMA	$19.83
200-Day SMA	$22.77
RSI (14)	63.67
Beta	0.90
52-Week High	$31.21
52-Week Low	$16.66

Volume Today	111.47K
Avg Daily Volume (30D)	168.21K
Relative Volume	0.66x
Volatility (10D)	37.57
Volatility (30D)	39.14
Free Float	69.18%

Analyst Consensus

HOLD

Current Price $20.91

Mean Target $22.00

52W Low$16.66 52W High$31.21

Current

Target

$16.66 $31.21

Current Analyst target

+5.21% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SCM4W2

ISINUS03209R1032

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.